Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

US FDA Requests Additional Data on Takeda’s Alogliptin

Takeda Pharmaceuticals have suffered a key setback after US regulators rejected their type 2 diabetes therapy, alogliptin, and the fixed-dose combination of the medicine with Takeda’s Actos. Actos lost patent protection in 2011, and generic versions of the drug are anticipated to hit the marketplace later this year. The business received a second complete response

Continue Reading

PAS reverses NICE rejection of Takeda’s Mepact

  Takeda’s Mepact (mifamurtide) has been recommended by the National Institute for Health and Clinical Excellence (NICE) as a treatment for young patients with osteosarcoma, when it is made available to the NHS at reduced cost under a patient access scheme (PAS). In a Final Appraisal Determination (FAD) which reverses the negative FAD published by

Continue Reading